Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Transplant Cell Ther. 2022 Jul;28(7):398.e1-398.e9. doi: 10.1016/j.jtct.2022.05.005. Epub 2022 May 13.
The effect of single or multiple mismatches at each HLA locus on outcomes after cord blood transplantation (CBT) is controversial. We analyzed the effects of single or multiple HLA locus mismatches on the outcomes after single CBT using Japanese registry data from the Japan Society for Hematopoietic Cell Transplantation. Patients age ≥16 years with acute leukemia and myelodysplastic syndromes who underwent their first CBT between 2003 and 2017 (n = 4074) were included. The effect of the number of HLA locus mismatches (0, 1, or 2 for the HLA-A, -B, -C, and -DRB1 loci) on outcomes was analyzed after adjusting for other significant variables. The patient cohort had a median age of 54 years. The median total nucleated and CD34 cell doses were 2.6 × 10/kg and .8 × 10/kg, respectively. The number of CBTs with single or double mismatches were 2099 and 292, respectively, for the HLA-A locus, 2699 and 341 for the HLA-B locus, 2555 and 609 for the HLA-C locus, and 2593 and 571 for the HLA-DRB1 locus. Single and double HLA-DRB1 mismatches were associated with a higher risk of grade II-IV acute graft-versus-host disease (GVHD; single: hazard ratio [HR], 1.29, P < .001; double: HR, 1.49, P < .001; P for trend <.001). Single and double mismatches at HLA-DRB1 as well as single mismatches at HLA-A and HLA-B also were associated with grade III-IV acute GVHD. Single and double HLA-B mismatches and double HLA-DRB1 mismatches were associated with a high risk of nonrelapse mortality (NRM). On the other hand, double mismatches at HLA-A or HLA-DRB1 and single mismatches at HLA-B were associated with a lower risk of relapse. HLA-DRB1 double mismatch was associated with high risk of grade II-IV and grade III-IV acute GVHD and NRM but lower risk of relapse. Not only the locus mismatch, but also the number of mismatches, should be considered in cord blood unit selection.
单或多个 HLA 位点错配对脐血移植(CBT)后结局的影响存在争议。我们使用日本造血细胞移植学会的日本注册数据,分析了单 CBT 后单个或多个 HLA 位点错配对结局的影响。纳入 2003 年至 2017 年间接受首次 CBT 的年龄≥16 岁的急性白血病和骨髓增生异常综合征患者(n=4074)。在调整其他重要变量后,分析了 HLA 位点错配数量(HLA-A、-B、-C 和-DRB1 位点为 0、1 或 2)对结局的影响。患者队列的中位年龄为 54 岁。中位总核细胞和 CD34 细胞剂量分别为 2.6×10/kg 和.8×10/kg。HLA-A 位点的 CBT 中,单或双错配的数量分别为 2099 和 292,HLA-B 位点为 2699 和 341,HLA-C 位点为 2555 和 609,HLA-DRB1 位点为 2593 和 571。单和双 HLA-DRB1 错配与 II-IV 级急性移植物抗宿主病(GVHD)风险增加相关(单:危险比[HR],1.29,P<.001;双:HR,1.49,P<.001;趋势 P<.001)。HLA-DRB1 单和双错配以及 HLA-A 和 HLA-B 单错配也与 III-IV 级急性 GVHD 相关。HLA-B 单和双错配以及双 HLA-DRB1 错配与非复发死亡率(NRM)高风险相关。另一方面,HLA-A 或 HLA-DRB1 双错配和 HLA-B 单错配与复发风险降低相关。HLA-DRB1 双错配与 II-IV 级和 III-IV 级急性 GVHD 以及 NRM 高风险相关,但与复发低风险相关。在选择脐血单位时,不仅应考虑位点错配,还应考虑错配数量。